| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802979101140 | 297910114 | VALPEROL F.C.TAB 40MG/TAB BTx30 (PVC/PCTFE-Alu blisters) (PVC/PCTFE-Alu blisters) | 3.93 | 4.12 | 5.68 |
| 05/2018 | 2802979102147 | 297910214 | VALPEROL F.C.TAB 80MG/TAB BTx30 (PVC/PCTFE-Alu blisters) (PVC/PCTFE-Alu blisters) | 3.48 | 3.65 | 05.04 |
| 05/2018 | 2802979103144 | 297910314 | VALPEROL F.C.TAB 160MG/TAB BTx30 (PVC/PCTFE-Alu blisters) (PVC/PCTFE-Alu blisters) | 4.29 | 4.50 | 6.20 |
For the treatment of hypertension.
Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Absolute bioavailability = 23% with high variability
The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
* 17 L
* 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]